Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology, particularly for the treatment and prevention of cancer. Its primary programs include a chimeric antigen receptor T-cell (CAR-T) therapy targeting ovarian cancer through a novel FSHR-directed approach, designed to engineer patients' immune cells against solid tumors. The company also advances innovative vaccine platforms, such as an α-lactalbumin-based vaccine initially targeting triple negative breast cancer (TNBC), the most lethal form of breast cancer, with extensions to ovarian cancer and exploratory efforts in lung, colon, and prostate cancers. These immunopreventive technologies aim to harness the body's immune system for early detection and proactive intervention. Anixa Biosciences Inc. operates in the high-stakes field of immuno-oncology, emphasizing CAR-T therapeutics and preventive vaccines to improve outcomes in hard-to-treat malignancies. Founded in 1982 and headquartered in San Jose, California, it continues to advance its pipeline through clinical trials and intellectual property expansion.